Abstract:In this study, oxaliplatin (OX) liposomes surface-modified with glycyrrhetinic acid (GA) were developed by the film-dispersion method. Their morphology, physical and chemical properties, and in vitro release performance were investigated. The transmission electron microscope (TEM) image showed that most liposomes were spherical particles with similar size and uniform dispersion. Both OX-liposomes and GA-OX-liposomes had an average size of 90 nm. They were negatively charged, with zeta potentials of -20.6 and -21.3 mV, respectively, and the entrapment efficiency values of both were higher than 94%. In vitro data showed that the application of liposomes could prolong the OX release. The relatively high correlation coefficient values obtained from analyzing the amount of drug released versus the square root of time depicted that release followed the Weibull model. No significant changes were observed after the addition of GA to the liposomes. In vivo, the relatively long time to reach the maximum plasma concentration of OX-liposomes suggested a sustained-release profile of liposomes, which was consistent with the results of the in vitro release study. The increased area under the curve and maximum plasma concentration of OX-liposomes and GA-OX-liposomes demonstrated an increased absorption. The drug concentration in tissues indicated that the GA-modified liposomes delivered OX mainly to liver after intravenous administration. In addition, no severe signs, such as appearance of epithelial necrosis or sloughing of epithelial cells, were detected in histology studies.

In Vitro and in Vivo Studies of Galactose-Modified Liver-Targeting Liposomes.

Preparation and Characterization of Galactosylated Bovine Serum Albumin Nanoparticles for Liver-Targeted Delivery of Oridonin.

Galactosylated bovine serum albumin nanoparticles for parenteral delivery of oridonin: tissue distribution and pharmacokinetic studies.

Galactosylated Chitosan Nanoparticles for Hepatocyte-Targeted Delivery of Oridonin

In Vivo Studies On The Oridonin-Loaded Nanostructured Lipid Carriers

In vitro and in vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers

In vitro and in vivo study of Gal-OS self-assembled nanoparticles for liver-targeting delivery of doxorubicin.

Galactose-decorated pH-responsive nanogels for hepatoma-targeted delivery of oridonin.

A Novel Glycyrrhetinic Acid-Modified Oxaliplatin Liposome for Liver-Targeting and in Vitro/vivo Evaluation.

Galangin-loaded, Liver Targeting Liposomes: Optimization and Hepatoprotective Efficacy

Preparation and characterization of galactose-modified liposomes by a nonaqueous enzymatic reaction

In Vitro and in Vivo Antitumor Activity of Oridonin Nanosuspension

Synthesis, characterization, in vitro and in vivo evaluation of PEGylated oridonin conjugates.

Oridonin loaded peptide nanovesicles alleviate nonalcoholic fatty liver disease in mice

Comparative Studies on Glycerol Monooleate- and Phytantriol-Based Cubosomes Containing Oridonin in Vitro and in Vivo.

Oridonin Nanosuspension Enhances Anti-Tumor Efficacy in SMMC-7721 Cells and H22 Tumor Bearing Mice

Oridonin-Loaded Nanoparticles Inhibit Breast Cancer Progression Through Regulation of ROS-Related Nrf2 Signaling Pathway

Biodegradable self-assembled MPEG-PCL micelles for hydrophobic oridonin delivery in vitro.

Promising Galactose-Decorated Biodegradable Poloxamer 188-PLGA Diblock Copolymer Nanoparticles of Resibufogenin for Enhancing Liver Cancer Therapy

Oridonin-loaded poly(ε-caprolactone)–poly(ethylene oxide)–poly(ε-caprolactone) copolymer nanoparticles: Preparation, characterization, and antitumor activity on mice with transplanted hepatoma

Oridonin restores hepatic lipid homeostasis in an LXRα-ATGL/EPT1 axis-dependent manner